Srikripa Devarakonda
Stock Analyst at Truist Financial
(4.92)
# 222
Out of 5,119 analysts
531
Total ratings
56.3%
Success rate
24.6%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Reiterated: Buy | $112 | $53.69 | +108.60% | 41 | Nov 6, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $709 → $743 | $399.63 | +85.92% | 16 | Nov 4, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,612 | $1,354.00 | +19.05% | 40 | Oct 30, 2026 | |
| INCY Incyte | Reiterated: Hold | $115 | $119.65 | -3.89% | 39 | Oct 27, 2026 | |
| IVA Inventiva | Reiterated: Buy | $18 | $3.80 | +373.68% | 8 | Oct 26, 2026 | |
| SRRK Scholar Rock Holding | Reiterated: Buy | $77 | $46.94 | +64.04% | 35 | Oct 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $70 | $62.14 | +12.65% | 23 | Oct 13, 2026 | |
| AXSM Axsome Therapeutics | Initiated Coverage: Buy | $285 | $132.37 | +115.31% | 1 | Sep 23, 2026 | |
| EWTX Edgewise Therapeutics | Reiterated: Buy | n/a | $45.04 | - | 35 | Sep 23, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $57 | $18.90 | +201.59% | 6 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $11.88 | +152.53% | 14 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $132.04 | - | 25 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $164 | $72.77 | +125.37% | 1 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.03 | - | 9 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $43 → $59 | $48.85 | +20.78% | 7 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $10 → $8.68 | $6.41 | +35.41% | 16 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $51.35 | +71.37% | 11 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.08 | - | 4 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.40 | - | 1 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $17 | $10.17 | +67.16% | 10 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $136 | $131.73 | +3.24% | 23 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $13.25 | - | 1 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $9.36 | - | 21 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.9065 | - | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $460.42 | n/a | 15 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $139 → $214 | $114.41 | n/a | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $15.30 | n/a | 15 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $812 | $904.35 | n/a | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $83.85 | n/a | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.77 | n/a | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $142 | $248.35 | n/a | 12 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.5668 | n/a | 7 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $291.31 | n/a | 7 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $146.73 | n/a | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $29.39 | n/a | 10 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 15 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.9377 | n/a | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $76.00 | n/a | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $8.41 | n/a | 13 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $38 | $0.000001 | n/a | 7 | Mar 20, 2023 |
Cytokinetics
Nov 6, 2026
Reiterated: Buy
Price Target: $112
Current: $53.69
Upside: +108.60%
Madrigal Pharmaceuticals
Nov 4, 2026
Reiterated: Buy
Price Target: $709 → $743
Current: $399.63
Upside: +85.92%
Eli Lilly and Company
Oct 30, 2026
Reiterated: Buy
Price Target: $1,612
Current: $1,354.00
Upside: +19.05%
Incyte
Oct 27, 2026
Reiterated: Hold
Price Target: $115
Current: $119.65
Upside: -3.89%
Inventiva
Oct 26, 2026
Reiterated: Buy
Price Target: $18
Current: $3.80
Upside: +373.68%
Scholar Rock Holding
Oct 20, 2026
Reiterated: Buy
Price Target: $77
Current: $46.94
Upside: +64.04%
Bristol-Myers Squibb Company
Oct 13, 2026
Reiterated: Buy
Price Target: $70
Current: $62.14
Upside: +12.65%
Axsome Therapeutics
Sep 23, 2026
Initiated Coverage: Buy
Price Target: $285
Current: $132.37
Upside: +115.31%
Edgewise Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $45.04
Upside: -
NewAmsterdam Pharma Company
Sep 22, 2026
Reiterated: Buy
Price Target: $57
Current: $18.90
Upside: +201.59%
Sep 2, 2026
Reiterated: Buy
Price Target: $30
Current: $11.88
Upside: +152.53%
Sep 1, 2026
Reiterated: Buy
Price Target: n/a
Current: $132.04
Upside: -
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $164
Current: $72.77
Upside: +125.37%
Aug 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.03
Upside: -
Aug 13, 2026
Reiterated: Buy
Price Target: $43 → $59
Current: $48.85
Upside: +20.78%
Aug 10, 2026
Rated: Hold
Price Target: $10 → $8.68
Current: $6.41
Upside: +35.41%
Aug 10, 2026
Reiterated: Buy
Price Target: $88
Current: $51.35
Upside: +71.37%
Jul 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.08
Upside: -
Jul 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.40
Upside: -
Jul 2, 2026
Reiterated: Buy
Price Target: $11 → $17
Current: $10.17
Upside: +67.16%
Jun 29, 2026
Rated: Buy
Price Target: $136
Current: $131.73
Upside: +3.24%
Jun 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $13.25
Upside: -
May 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.36
Upside: -
Mar 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.9065
Upside: -
Nov 5, 2025
Reiterated: Hold
Price Target: n/a
Current: $460.42
Upside: n/a
Nov 3, 2025
Reiterated: Buy
Price Target: $139 → $214
Current: $114.41
Upside: n/a
Oct 30, 2025
Reiterated: Buy
Price Target: $23
Current: $15.30
Upside: n/a
Oct 29, 2025
Reiterated: Buy
Price Target: $812
Current: $904.35
Upside: n/a
Oct 10, 2025
Reiterated: Buy
Price Target: $84
Current: $83.85
Upside: n/a
Aug 4, 2025
Rated: Hold
Price Target: n/a
Current: $0.77
Upside: n/a
Jul 21, 2025
Downgraded: Hold
Price Target: $142
Current: $248.35
Upside: n/a
Jul 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.5668
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $291.31
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $146.73
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $29.39
Upside: n/a
Jan 28, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Dec 23, 2024
Rated: Hold
Price Target: n/a
Current: $0.9377
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: n/a
Current: $76.00
Upside: n/a
Oct 18, 2024
Rated: Buy
Price Target: $15
Current: $8.41
Upside: n/a
Mar 20, 2023
Downgraded: Hold
Price Target: $40 → $38
Current: $0.000001
Upside: n/a